|Slideshows|December 23, 2019

Exploring the Proactive Model

How much do you know about the innovative Proactive Consultation-Liaison (C-L) Psychiatry model? Learn more and test your knowledge in this interactive quiz.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Earn CME Credit With Psychiatric Times: Don’t Miss These Articles

ByPsychiatric Times Editors

July 24th 2026

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

ByLeah Kuntz

June 29th 2026

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

BySophia Hashmi,Hazem Shahin, MD

June 24th 2026

Which Patients Are Less Likely to Believe They Have a Comorbid Mental Health Disorder?

ByMark Zimmerman, MD

May 27th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Exploring the Proactive Model

Related Content

Earn CME Credit With Psychiatric Times: Don’t Miss These Articles

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

Which Patients Are Less Likely to Believe They Have a Comorbid Mental Health Disorder?

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD